Tumor‐derived lactate is a key metabolite contributing to the immunosuppressive microenvironment of solid tumors.[28] STING activation has been reported to inhibit aerobic glycolysis in tumor cells, thereby reducing lactate secretion in a manner independent of innate immunity.[29] Consistent with these findings, both TACTIC and CS were shown to suppress the secretion of lactate from tumor cells (Figure S12, Supporting Information), indicating their potential to mitigate tumor‐induced immunosuppression. Here, STING1 is linked to neoplasm.